AUM Biosciences (AUM) today announced the successful completion of $27 million series A funding round. This will fuel AUM’s vision of developing a world class biotech pipeline focused on drugging what many consider as the undruggable targets, as well as addressing the need to delay and overcome resistance to targeted drugs in oncology.
Travecta Therapeutics, announces today it has raised an additional $12 million in financing, closing its Series A round at a total of $27 million.
LIFE science startups hoping for a big break can now look to a new Singapore-based cash cow for funding.European asset manager Tikehau Capital and Sprim Ventures, the venture arm of global healthcare consultancy Sprim, have teamed up to launch a venture capital (VC) fund for early-stage investments.The committed capital for the fund, dubbed TKS1, is […]
PHILADELPHIA–(BUSINESS WIRE)–Vanteres, an innovative biotech company leveraging its biomedical research expertise to develop actively transported lysophospholipids, announces new evidence that demonstrates the critical role of LPC-DHA in normal fetal and infant brain development.
- 1
- 2